ANALYTICAL QBD INTEGRATED RP-HPLC METHOD DEVELOPMENT AND OPTIMIZATION FOR HIGH-PRECISION QUANTIFICATION OF IBRUTINIB IN HYBRID NANOCARRIER SYSTEMS
DOI:
https://doi.org/10.22159/ijap.2025v17i5.54683Keywords:
Reversed-phase high-performance liquid chromatography, Ibrutinib, Design of experiments, Quality by design, Box-behnken design, ValidationAbstract
Objective: This study optimizes, develops, and validates the reversed-phase high-performance liquid chromatography (RP-HPLC) assay to measure Ibrutinib (IBR) in bulk and nanoformulations. It is a highly sensitive and specific method.
Methods: Chromatographic optimization was addressed using a methodical Design of Experiments (DoE) approach. Key method parameters (CMPs) were screened using the Taguchi Orthogonal Array (OA) design, and the outcomes were optimized using the Box-Behnken Design (BBD).
Results: The optimal settings were the Acetonitrile (ACN) (50% v/v) as the mobile phase, a 1.043 ml/min flow rate, and a column oven temperature of 26 °C. Under these conditions, the following results were obtained: theoretical plates of 13,5050±19.9, a peak area of 171500.66±324.94 mV-min, a Retention time (Rt) of 8.12±0.011 min, and a Tailing factor (Tf) of 1.21±0.001. The procedure showed good linearity with detection and quantification limits of 4.74 ng/ml and 15.8 ng/ml, respectively, for the concentration range of 50-5000 ng/ml (R2=0.9997). Validation verified that the approach met regulatory requirements for precision, specificity, sensitivity, accuracy, and robustness. Moreover, the method showed selectivity towards IBR even in degradation products.
Conclusion: The suggested RP-HPLC technique is good for regular pharmaceutical examination of IBR formulations. It has been effectively applied to identify and quantify IBR in hybrid nanocarriers and in in vitro drug release tests.
References
1. Kaur V, Swami A. Ibrutinib in CLL: a focus on adverse events, resistance and novel approaches beyond ibrutinib. Ann Hematol. 2017 Jul;96(7):1175-84. doi: 10.1007/s00277-017-2973-2, PMID 28342031.
2. Ran F, Liu Y, Wang C, Xu Z, Zhang Y, Liu Y. Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. Eur J Med Chem. 2022 Feb 5;229:114009. doi: 10.1016/j.ejmech.2021.114009, PMID 34839996.
3. Szklener K, Michalski A, Zak K, Piwonski M, Mandziuk S. Ibrutinib in the treatment of solid tumors: current state of knowledge and future directions. Cells. 2022 Jan;11(8):1338. doi: 10.3390/cells11081338, PMID 35456016.
4. Rizwanullah M, Alam M, Harshita MSR, Mir SR, Rizvi MM, Amin S. Polymer lipid hybrid nanoparticles: a next-generation nanocarrier for targeted treatment of solid tumors. Curr Pharm Des. 2020 Apr 24;26(11):1206-15. doi: 10.2174/1381612826666200116150426, PMID 31951163.
5. Elkady EF, Fouad MA, Mozayad AN. Application of box-behnken experimental design and response surface methodology for selecting the optimum RP-HPLC conditions for the simultaneous determination of methocarbamol indomethacin and betamethasone in their pharmaceutical dosage form. BMC Chem. 2022 Dec 12;16(1):114. doi: 10.1186/s13065-022-00908-9, PMID 36510282.
6. Kokilambigai KS, Lakshmi KS. Analytical quality by design-assisted RP-HPLC method for quantifying atorvastatin with green analytical chemistry perspective. J Chromatogr Open. 2022 Nov 1;2:100052. doi: 10.1016/j.jcoa.2022.100052.
7. Kannaiah KP, Chanduluru HK, Obaydo RH, Lotfy HM, Erk N, Krishnan M. Application of advanced environmentally benign assessment tools in determining ternary cardiovascular drug combination by RP-HPLC with analytical quality by design: application to stability indicating method evaluation. Sustain Chem Pharm. 2023 Oct 1;35:101197. doi: 10.1016/j.scp.2023.101197.
8. Borman P, Chatfield M, Nethercote P, Thompson D, Truman K. The application of quality by design to analytical methods. Pharm Technol. 2007;31(10):142-8.
9. Sathishbabu P, Hani U, Shakeela C, Hemanth Vikram PR, Ghazwani M, Osmani RA. A novel RP-HPLC method development and validation for simultaneous quantification of gefitinib and resveratrol in polymeric hybrid lipid nanoparticles and glioma cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Dec 1;1212:123483. doi: 10.1016/j.jchromb.2022.123483, PMID 36279777.
10. Prajapati P, Patel A, Desai A, Shah P, Shakar Pulusu V, Shah S. Comprehensive strategy of white analytical chemistry and analytical quality by design to sensitive spectrofluorimetric method for in vitro drug release kinetic study of Ibrutinib-loaded nanostructured lipid carriers for leukemia via lymphatic targeting. Microchem J. 2024 Mar 1;198:110147. doi: 10.1016/j.microc.2024.110147.
11. Akbel E, Gungor S, Bulduk I. Alternative analytical methods for ibrutinib quantification in pharmaceutical formulation: a statistical comparison. Rev Anal Chem. 2022 Jan 1;41(1):146-57. doi: 10.1515/revac-2022-0039.
12. Garcia Cansino L, Boltes K, Marina ML, Garcia MA. Enantioseparation and ecotoxicity evaluation of ibrutinib by electrokinetic chromatography using single and dual systems. Talanta. 2023 Dec 1;265:124783. doi: 10.1016/j.talanta.2023.124783, PMID 37348354.
13. Albuquerque LF, Souto MV, Saldanha Araujo F, Carvalho JL, Gratieri T, Cunha-Filho M. Development and validation of a chromatographic method for ibrutinib determination in human and porcine skin. Chemistry. 2024;6(2):272-82. doi: 10.3390/chemistry6020014.
14. Chatki PK, Mahajan UN. Eco-friendly liquid chromatography method for the quantification of ibrutinib in a pharmaceutical dosage form. Biomed Chromatogr. 2024 Feb;38(2):e5792. doi: 10.1002/bmc.5792, PMID 38017613.
15. Konduru N, Gundla R, Katari NK, Paidikondala K, Reddy AS, Jagadabi V. Development and validation of a stability indicating method for Ibrutinib: identification and separation of degradation products known and genotoxic impurities using RP-HPLC/PDA and QDa mass detectors. Anal Chem Lett. 2020;10(1):113-36. doi: 10.1080/22297928.2019.1673814.
16. Shamim A, Ansari MJ, Aodah A, Iqbal M, Aqil M, Mirza MA. QbD-engineered development and validation of a RP-HPLC method for simultaneous estimation of Rutin and ciprofloxacin HCl in Bilosomal nanoformulation. ACS Omega. 2023 Jun 20;8(24):21618-27. doi: 10.1021/acsomega.3c00956, PMID 37360463.
17. Ettaboina SK, Katakam LN, Dongala T. Development and validation of a stability indicating RP-HPLC method for the determination of erythromycin related impurities in topical dosage form. Pharm Chem J. 2022 Apr 1;56(1):131-7. doi: 10.1007/s11094-022-02610-5.
18. Pereira FJ, Rodriguez Cordero A, Lopez R, Robles LC, Aller AJ. Development and validation of an RP-HPLC-PDA method for determination of paracetamol caffeine and tramadol hydrochloride in pharmaceutical formulations. Pharmaceuticals (Basel). 2021 May;14(5):466. doi: 10.3390/ph14050466, PMID 34063393.
19. Bhatt DA, Rane SI. QbD approach to analytical RP-HPLC method development and its validation. Int J Pharm Pharm Sci. 2011;3(1):179-87.
20. Patel KY, Dedania ZR, Dedania RR, Patel U. QbD approach to HPLC method development and validation of ceftriaxone sodium. Futur J Pharm Sci. 2021 Dec;7(1):141. doi: 10.1186/s43094-021-00286-4.
21. Kelani KM, Elzanfaly ES, Saad AS, Halim MK, El Zeiny MB. Different greenness assessment perspectives for stability indicating RP-HPLC method used for the assay of isoxsuprine hydrochloride and four nephrotoxic and hepatotoxic photothermal degradation products. Microchem J. 2021 Dec 1;171:106826. doi: 10.1016/j.microc.2021.106826.
22. Alam P, Shakeel F, Taleuzzaman M, Foudah AI, Alqarni MH, Aljarba TM. Box-behnken design (BBD) application for optimization of chromatographic conditions in RP-HPLC method development for the estimation of thymoquinone in Nigella sativa seed powder. Processes. 2022 Jun;10(6):1082. doi: 10.3390/pr10061082.
23. Salwa KL, Kumar L. Quality by design driven analytical method (AQbD) development and validation of HPLC–UV technique to quantify rivastigmine hydrogen tartrate in lipidic nanocarriers: forced degradation and assessment of drug content and in vitro release studies. Microchem J. 2023 Oct 1;193:108944. doi: 10.1016/j.microc.2023.108944.
24. Beg S, Hasnain MS, Rahman M, Swain S. Introduction to quality by design (QbD): fundamentals principles and applications. In: Pharmaceutical quality by design. Amsterdam: Elsevier; 2019. p. 1-17. doi: 10.1016/B978-0-12-815799-2.00001-0.
25. Maddala SM, Parimi R, Elvina PK. A quality by design (QbD) strategy for developing and validating droxidopa in API and formulation using an RP-HPLC procedure ensuring regulatory compliance. Anal Chem Lett. 2025;15(2):328-48. doi: 10.1080/22297928.2024.2446893.
26. Deidda R, Orlandini S, Hubert P, Hubert C. Risk based approach for method development in pharmaceutical quality control context: a critical review. J Pharm Biomed Anal. 2018 Nov 30;161:110-21. doi: 10.1016/j.jpba.2018.07.050, PMID 30145448.
27. De Baere S, Eeckhaut V, Steppe M, De Maesschalck C, De Backer P, Van Immerseel F. Development of a HPLC–UV method for the quantitative determination of four short chain fatty acids and lactic acid produced by intestinal bacteria during in vitro fermentation. J Pharm Biomed Anal. 2013 Jun 1;80:107-15. doi: 10.1016/j.jpba.2013.02.032, PMID 23542733.
28. Marques SM, Salwa KL, Kumar L. Quality by design-based development of an eco-friendly HPLC method for the estimation of nisoldipine in nanoformulations: forced degradation studies and in vitro release studies. Sustain Chem Pharm. 2023 Dec 1;36:101254. doi: 10.1016/j.scp.2023.101254.
29. Miriam Marques S, Shirodkar RK, Kumar L. Analytical quality by design paradigm in development of a RP-HPLC method for the estimation of cilnidipine in nanoformulations: forced degradation studies and mathematical modelling of in vitro release studies. Microchem J. 2023 Oct 1;193:109124. doi: 10.1016/j.microc.2023.109124.
30. Afzal M, Muddassir M, Alarifi A, Ansari MT. Box-behnken assisted validation and optimization of an RP-HPLC method for simultaneous determination of domperidone and lansoprazole. Separations. 2021 Jan;8(1):5. doi: 10.3390/separations8010005.
31. Alruwaili NK. Analytical quality by design approach of reverse phase high performance liquid chromatography of atorvastatin: method development optimization validation and the stability indicated method. Int J Anal Chem. 2021;2021(1):8833900. doi: 10.1155/2021/8833900, PMID 33628253.
32. Recber T, Timur SS, Erdogan Kablan S, Yalçın F, Karabulut TC, Neslihan Gursoy R. A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies. J Pharm Biomed Anal. 2022 May 30;214:114693. doi: 10.1016/j.jpba.2022.114693, PMID 35276385.
33. Kowalska M, Wozniak M, Kijek M, Mitrosz P, Szakiel J, Turek P. Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product. Sci Rep. 2022;12(1):1. doi: 10.1038/s41598-021-99269-x, PMID 34992227.
34. Annadi MA, Zahar NME, Abdel Sattar NEDA, H Mohamed E, A Mahmoud S, S Attia M. Development and validation of molnupiravir assessment in bulk powder and pharmaceutical formulation by the RP-HPLC-UV method. RSC Advances. 2022;12(53):34512–9.
35. Ramanunny AK, Wadhwa S, Gulati M, Gupta S, Porwal O, Jha NK. Development and validation of RP-HPLC method for 1-Acetoxychavicol acetate (ACA) and its application in optimizing the yield of ACA during its isolation from Alpinia galanga extract as well as its quantification in nanoemulsion. S Afr J Bot. 2022 Sep 1;149:887-98. doi: 10.1016/j.sajb.2021.10.012.
36. Kumar G, Mullick P, Nandakumar K, Mutalik S, Rao CM. Box–behnken design-based development and validation of a reverse-phase HPLC analytical method for the estimation of paclitaxel in cationic liposomes. Chromatographia. 2022 Jul 1;85(7):629-42. doi: 10.1007/s10337-022-04172-w.
37. Mozayad AN, Fouad MA, Elkady EF. Utilizing experimental design and desirability function in optimizing RP-HPLC method for simultaneous determination of some skeletal muscle relaxants and analgesics. Sci Rep. 2024 May 6;14(1):10360. doi: 10.1038/s41598-024-58381-4, PMID 38710733.
38. Bedogni G, Azcarate F, Seremeta K, Okulik N, Salomon C, Boschetti C. Development of a fast RP-HPLC method for the separation of nifurtimox and its forced degradation products through a design of experiment approach. J Mol Liq. 2024 Apr 1;399:124293. doi: 10.1016/j.molliq.2024.124293.
39. Reddy Gopireddy R, Maruthapillai A, Mahapatra S, Tamilselvi M. Development and validation of HPLC method for enantioseparation of Ibrutinib on immobilized chiral stationary phase. Mater Today Proc. 2022 Jan 1;50:384-7. doi: 10.1016/j.matpr.2021.08.358.
40. Al Hakkani MF, Ahmed N, Abbas AA, Hassan MH. Cefoperazone rapidly and sensitive quantitative assessment via a validated RP-HPLC method for different dosage forms in use stability and antimicrobial activities. BMC Chem. 2023 Jul 12;17(1):72. doi: 10.1186/s13065-023-00989-0, PMID 37438790.
41. Sen S, Ranjan OP. A quality by design (QbD) driven gradient high-performance liquid chromatography method development for the simultaneous estimation of dasatinib and nilotinib in lipid nanocarriers. J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Aug 1;1243:124229. doi: 10.1016/j.jchromb.2024.124229, PMID 38991258.
42. Anwer MK, Ali EA, Iqbal M, Ahmed MM, Aldawsari MF, Saqr AA. Development of sustained-release baricitinib-loaded lipid polymer hybrid nanoparticles with improved oral bioavailability. Molecules. 2021;27(1):168. doi: 10.3390/molecules27010168, PMID 35011397.
43. Khan MA, Khan S, Kazi M, Alshehri SM, Shahid M, Khan SU. Norfloxacin-loaded lipid polymer hybrid nanoparticles for oral administration: fabrication characterization in silico modelling and toxicity evaluation. Pharmaceutics. 2021;13(10):1632. doi: 10.3390/pharmaceutics13101632, PMID 34683925.
44. RR. Stability indicating RP-HPLC method development and validation for the analysis of doxepin hydrochloride in bulk and pharmaceutical dosage form. Int J Pharm Pharm Sci. 2024 Apr 1;16(4):27-35. doi: 10.22159/ijpps.2024v16i4.50126.
45. Du M, Ouyang Y, Meng F, Zhang X, Ma Q, Zhuang Y. Polymer lipid hybrid nanoparticles: a novel drug delivery system for enhancing the activity of Psoralen against breast cancer. Int J Pharm. 2019 Apr 20;561:274-82. doi: 10.1016/j.ijpharm.2019.03.006, PMID 30851393.
46. Katolkar P, Jaiswal S. Analytical method development and validation for the estimation of cyamemazine tartrate in formulation by RP-HPLC with stability indicating. Asian J Pharm Clin Res. 2022 Sep 7;15(9):28-32. doi: 10.22159/ajpcr.2022.v15i9.45154.
47. Saini S, Sharma T, Patel A, Kaur R, Tripathi SK, Katare OP. QbD-steered development and validation of an RP-HPLC method for quantification of ferulic acid: rational application of chemometric tools. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 15;1155:122300. doi: 10.1016/j.jchromb.2020.122300, PMID 32771967.
48. Ibrahim AM, Hendawy HA, Hassan WS, El Sayed HM, Shalaby A. Response surface and tolerance analysis approach for optimizing HPLC method. Microchem J. 2019 May 1;146:220-6. doi: 10.1016/j.microc.2019.01.007.
49. Alam P, Noman OM, Herqash RN, Almarfadi OM, Akhtar A, Alqahtani AS. Response surface methodology (RSM)-based optimization of ultrasound-assisted extraction of sennoside A, sennoside B, aloe-emodin, emodin, and chrysophanol from Senna alexandrina (Aerial Parts): HPLC-UV and antioxidant analysis. Molecules. 2022 Jan;27(1):298. doi: 10.3390/molecules27010298, PMID 35011528.
50. Prajapati P, Rana B, Pulusu VS, Mishra A. Multipurpose RP-HPLC method for simultaneous estimation of fixed dose combinations of anti-diabetic drugs: integrating green economical and robust approaches with design of experiments and white analytical chemistry. Chem Afr. 2024 Apr 1;7(3):1385-400. doi: 10.1007/s42250-023-00835-9.
51. Saha M, Gupta A, Shetty S, Mutalik S, Nandakumar K, Raghu Chandrashekar H. DoE-aided optimization of RP-HPLC method for simultaneous estimation of amoxicillin and tinidazole loaded mucoadhesive GRDDS formulation for the treatment of H. pylori. Chromatographia. 2024 Sep 1;87(9):533-48. doi: 10.1007/s10337-024-04346-8.
52. Kumar P, Mangla B, Beg S, Afzal O, Saleh Alfawaz Altamimi A, Almalki WH. Optimization and validation of stability indicating RP-HPLC method for the quantification of gefitinib in bulk drug and nanoformulations: an application towards in vitro and ex vivo performance evaluation. Arab J Chem. 2022 Dec 1;15(12):104333. doi: 10.1016/j.arabjc.2022.104333.
53. Imam SS, Alshehri S, Altamimi MA, Hussain A, Qamar W, Gilani SJ. Formulation of piperine chitosan-coated liposomes: characterization and in vitro cytotoxic evaluation. Molecules. 2021;26(11):3281. doi: 10.3390/molecules26113281, PMID 34072306.
Published
How to Cite
Issue
Section
Copyright (c) 2025 PRAGATHI DEVANAND BANGERA, MAHESHA KEERIKKADU , VAMSHI KRISHNA TIPPAVAJHALA , Mahalaxmi Rathnanand
This work is licensed under a Creative Commons Attribution 4.0 International License.
